The favourable patent environment in Iceland, Malta and Turkey enables Medis to develop, manufacture and stockpile new products before patents have expired in other EU countries. Our principal development site is in Iceland; another site in Malta supports a growing portfolio.

The registration function in Iceland was strengthened in 2003. The unit compiles and files growing numbers of Marketing Authorisation Applications to authorities in the EU. The quality of Medis development dossiers and this dedicated expertise in regulatory affairs has ensured rapid registration of products in nearly 40 countries.